Imatinib Krka D.D.

Imatinib, the active ingredient in Imatinib Krka D.D., is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients and is administered under medical supervision in specialized oncology settings.

GNH USA supplies Imatinib Krka D.D. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Imatinib acts on specific tyrosine kinase‑driven malignancies, providing targeted therapy for several cancers.

Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces cytogenetic remission. Gastrointestinal stromal tumor (GIST): inhibits tumor growth and improves progression‑free survival. Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control when combined with chemotherapy.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: swelling of the hands, feet or periorbital area. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: reduced heart function or congestive symptoms.

When prescribing imatinib, clinicians should observe several safety measures to minimize risk.

- Monitor blood counts: perform regular complete blood count tests to detect cytopenias. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate cardiac status: baseline and periodic echocardiograms for patients with cardiac history. - Avoid use in pregnancy unless benefits outweigh risks: discuss potential fetal effects with the patient. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise imatinib levels and toxicity. - CYP3A4 inducers (e.g., rifampin): can lower drug exposure and reduce efficacy. - Co‑administration with other tyrosine kinase inhibitors: increases risk of overlapping toxicities.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may affect INR, requiring closer anticoagulation monitoring. - Diuretics: may exacerbate fluid retention and edema, necessitating dose adjustments.